QMed, Inc. Receives NASDAQ Letter( EATONTOWN N.J. Dec. 24 /- QMed In...),Health
EATONTOWN, N.J., Dec. 24 /PRNewswire-FirstCall/ -- QMed, Inc., (Nasdaq: QMED) today announced that it has received a letter from Nasdaq indicating, that for the last 30 business days, the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4310(c)(4) (the "Rule"). Therefore, in accordance with Marketplace Rule 4310(c) (8) (D), the Company will be provided 180 calendar days, or until June 16, 2008 to regain compliance. If, at any time before June 16, 2008, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will be provided written notification that it complies with the Rule.
If compliance with this Rule cannot be demonstrated by June 16, 2008, Nasdaq Staff will determine whether the Company meets The Nasdaq Capital Market initial listing criteria as set forth in Marketplace Rule 4310(c), except for the bid price requirement. If it meets the initial listing criteria, the Company will be notified that it will be granted an additional 180 calendar day compliance period. If the Company is not eligible for an additional compliance period, the Company will receive written notification from Nasdaq Staff that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to delist its securities to a Listing Qualifications Panel.
About QMed, Inc.
QMed has developed evidence-based clinical information management systems for use by health plan customers. The QMed systems incorporate Disease Management services to patients and decision support to physicians. The Company's subsidiaries have specialized in serving high-risk populations of Medicare beneficiaries.
Except for historical information contained herein, matters discussed
in this news release are forward-looking statements that involve risks and
uncertainties. They incl
'/>"/>
| SOURCE QMed, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
2. QMed, Inc. Extends Agreement & Receives $550,000 Performance Bonus
3. QMed, Inc. Reports Third Quarter Results
4. QMed, Inc. Retains Lazard Middle Market
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |